n.a. (BPAX)

55.05
0.69 1.24
NASDAQ
Prev Close 55.74
Open 56.64
Day Low/High 54.22 / 56.64
52 Wk Low/High 12.79 / 56.99
Volume 182.41K
Exchange NASDAQ
P/E Ratio N/A
Div & Yield N.A. (N.A)
Biotech Stock Mailbag: Cytori Therapeutics

Biotech Stock Mailbag: Cytori Therapeutics

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

BioSante Pharmaceuticals, Inc. To Present At Two Upcoming Investor Conferences

BioSante Pharmaceuticals, Inc. To Present At Two Upcoming Investor Conferences

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at two upcoming investors conferences on May 24, 2011.

BioSante Pharmaceuticals Reports First Quarter Financial Results And Recent Developments

BioSante Pharmaceuticals Reports First Quarter Financial Results And Recent Developments

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today reported on its financial results for the first quarter, cash balance as of March 31, 2011 and recent developments.

BioSante Pharmaceuticals, Inc. To Present At JMP Securities Research Conference

BioSante Pharmaceuticals, Inc. To Present At JMP Securities Research Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at The JMP Securities Tenth Annual Research Conference.

BioSante Pharmaceuticals, Inc. To Present At The Deutsche Bank Annual Health Care Conference

BioSante Pharmaceuticals, Inc. To Present At The Deutsche Bank Annual Health Care Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the 36 th Annual Deutsche Bank Health Care Conference to be held at the InterContinental Hotel, Boston from May 2-4, 2011.

BioSante Pharmaceuticals Announces Pancreatic And Prostate Cancer Vaccine License

BioSante Pharmaceuticals Announces Pancreatic And Prostate Cancer Vaccine License

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced it has licensed its Pancreas Cancer Vaccine and Prostate Cancer Vaccine to Aduro BioTech, a clinical-stage immunotherapy company, solely for use in ...

BioSante Pharmaceuticals Announces Teva New Drug Application For Bio-T-Gel™

BioSante Pharmaceuticals Announces Teva New Drug Application For Bio-T-Gel™

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that a New Drug Application (NDA) has been accepted for filing by the U.

BioSante Pharmaceuticals, Inc. To Present At Future Leaders In The Biotech Industry Conference

BioSante Pharmaceuticals, Inc. To Present At Future Leaders In The Biotech Industry Conference

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) will be presenting at Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel & Conference Center in New York City.

BioSante Pharmaceuticals To Host LibiGel® R&D Event In New York City

BioSante Pharmaceuticals To Host LibiGel® R&D Event In New York City

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) will host a review of female sexual dysfunction (FSD) and the safety of testosterone in women by independent experts, as well as an update of the LibiGel (testosterone gel)...

BioSante Pharmaceuticals Completes Enrollment In Both Pivotal LibiGel® Phase III Efficacy Trials

BioSante Pharmaceuticals Completes Enrollment In Both Pivotal LibiGel® Phase III Efficacy Trials

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that enrollment of subjects in the second of two pivotal Phase III LibiGel (testosterone gel) safety and efficacy trials has been completed.

BioSante Pharmaceuticals Reports Financial Results For 2010 And Clinical Development And Business Highlights

BioSante Pharmaceuticals Reports Financial Results For 2010 And Clinical Development And Business Highlights

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced financial results for the year ended December 31, 2010 and clinical development and business highlights.

Biotech Stock Mailbag: Cadence Pharma

Biotech Stock Mailbag: Cadence Pharma

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

BioSante Pharmaceuticals, Inc. To Present At Roth Annual Growth Stock Conference

BioSante Pharmaceuticals, Inc. To Present At Roth Annual Growth Stock Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at the Roth 23 rd Annual Growth Stock Conference.

BioSante Pharmaceuticals Closes $25.1 Million Registered Direct Offering

BioSante Pharmaceuticals Closes $25.1 Million Registered Direct Offering

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the closing of a previously announced sale of $25.

Biosante Stock Falls On Unusually High Volume (BPAX)

Biosante Stock Falls On Unusually High Volume (BPAX)

Biosante Pharmaceuticals (Nasdaq:BPAX) is trading at unusually high volume Friday with 7.6 million shares changing hands. It is currently at 4 times its average daily volume and trading down 19 cents (-8.8%).

BioSante Pharmaceuticals To Raise $25.1 Million In Registered Direct Offering

BioSante Pharmaceuticals To Raise $25.1 Million In Registered Direct Offering

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it has received commitments from several institutional investors to purchase $25.

BioSante, Wendy's: Small-Cap Winners

BioSante, Wendy's: Small-Cap Winners

TheStreet presents a rundown of the winners in the small-cap space during the day's trading.

BioSante’s Pancreas Cancer Vaccine Shows Survival Increase In Newly Published Study

BioSante’s Pancreas Cancer Vaccine Shows Survival Increase In Newly Published Study

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced publication of results from a Phase II clinical study that show BioSante’s Pancreas Cancer Vaccine increased the median survival of resected...

BioSante Pharmaceuticals Completes Enrollment In LibiGel® Phase III Efficacy Trial

BioSante Pharmaceuticals Completes Enrollment In LibiGel® Phase III Efficacy Trial

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that enrollment of subjects in the first of two pivotal Phase III LibiGel (testosterone gel) safety and efficacy trials has been completed.

BioSante Pharmaceuticals, Inc. To Present At Citi Global Health Care Conference

BioSante Pharmaceuticals, Inc. To Present At Citi Global Health Care Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at the 2011 Citi Global Health Care Conference.

BioSante Presents Data Showing Female Sexual Dysfunction Is A Significant Unmet Medical Need

BioSante Presents Data Showing Female Sexual Dysfunction Is A Significant Unmet Medical Need

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), a pharmaceutical company developing products for the treatment of female sexual health, presented critical female sexual dysfunction market data at the ISSWSH (The ...

BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data In Phase III Program

BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data In Phase III Program

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), presented positive safety data in its ongoing LibiGel Phase III clinical development program, at the annual meeting of ISSWSH on February 12, 2011.

BioSante Pharmaceuticals, Inc. To Present LibiGel® Safety Study Update At BIO CEO & Investor Conference

BioSante Pharmaceuticals, Inc. To Present LibiGel® Safety Study Update At BIO CEO & Investor Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at the 2011 BIO CEO & Investor Conference.

BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data In Phase III Program

BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data In Phase III Program

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced positive safety data in its ongoing LibiGel Phase III clinical development program.

Biosante Stock Falls On Unusually High Volume (BPAX)

Biosante Stock Falls On Unusually High Volume (BPAX)

Biosante Pharmaceuticals (Nasdaq:BPAX) is trading at unusually high volume Wednesday with 5.5 million shares changing hands. It is currently at 4 times its average daily volume and trading down 15 cents (-6.5%).

BioSante Pharmaceuticals, Inc. To Provide Update On LibiGel® Safety Study At International Society For The Study Of Women’s Sexual Health Meeting

BioSante Pharmaceuticals, Inc. To Provide Update On LibiGel® Safety Study At International Society For The Study Of Women’s Sexual Health Meeting

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that it will provide a LibiGel safety study update, and is supporting two clinical symposia at the Annual Meeting of The International Society for the Study...

BioSante Announces FDA Orphan Drug Designation For Its Melanoma Cancer Vaccine

BioSante Announces FDA Orphan Drug Designation For Its Melanoma Cancer Vaccine

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the receipt of Orphan Drug designation for its Melanoma Cancer Vaccine in the treatment of stage IIb to IV melanoma, from the FDA’s Office of Orphan...

BioSante Pharmaceuticals Confirms Female Sexual Dysfunction As An Unmet Medical Need

BioSante Pharmaceuticals Confirms Female Sexual Dysfunction As An Unmet Medical Need

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), a pharmaceutical company developing products for the treatment of female sexual health, today announced results of a survey of over 100 Obstetrician/Gynecologists and ...

BioSante Pharmaceuticals Closes $18 Million Registered Direct Offering To Fund LibiGel® For Female Sexual Dysfunction

BioSante Pharmaceuticals Closes $18 Million Registered Direct Offering To Fund LibiGel® For Female Sexual Dysfunction

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced closing of a previously announced sale of an aggregate of $18 million of securities in a registered direct offering.

Beazer, Sears, KBR Are Big Market Movers

Beazer, Sears, KBR Are Big Market Movers

Beazer, Sears, KBR, Rare Element Resources, Hecla are big market movers Tuesday